"The pill" goes natural with potential new bestseller
This article was originally published in Scrip
Teva’s NOMAC/E2 has become the first monophasic natural oestrogen contraceptive to be approved in the EU. Datamonitor believes that a perceived increased safety and a global launch will drive sales of the product, making it one the leading hormonal contraceptives brands with sales in excess of $350m. However, to maximize its potential Teva will hope that post marketing studies show improved safety over synthetic oestrogen contraceptives.
You may also be interested in...
Novartis’s SMC021 failed to meet main fracture reduction endpoints in osteoporosis Phase III trial. While the result is arguably unsurprising for a calcitonin candidate, it is a setback for other companies such as Tarsa Therapeutics aiming to stimulate growth of the class. Tarsa may now struggle to secure a partner willing to bring its pipeline drug Ostora to the market. Novartis is expected to discontinue development of SMC021 and focus on more attractive targets for osteoporosis treatment.
Merck admission that it has received a complete response letter from the FDA for its novel contraceptive Nomac E2 (nomegestrol acetate/17 beta estradiol) may spell the end for more than just this product, analysts at Datamonitor say.
Eli Lilly is poised to benefit from a windfall after FDA granted marketing authorisation for once daily Cialis (tadalafil) to treat men with BPH symptoms alone or with both BPH and erectile dysfunction. This is the first drug to offer this convenient option to patients. These new indications will provide Eli Lilly with an estimated additional $150m in annual sales for Cialis in the US.